ncRNA basic information
ncRNA ID:
MI0003644
ncRNA Database:
miRBase
ncRNA Name:
miR-630
ncRNA Type:
miRNA
ncRNA Expression:
up-regulated
ncRNA Method:
qPCR
ncRNA Target Gene:
IGF1R
ncRNA Pathway:
NA
Evidence (ncRNA-drug):
validated
drug basic information
Drug ID:
DB01259 (DB02584)
Drug Name:
Lapatinib
Drug Method:
We investigated the levels of intra- and extracellular miR-630 in cells and conditioned media from breast cancer cell lines with either innate- or acquired- resistance to HER-targeting lapatinib and neratinib, compared to their corresponding drug sensitive cell lines, using qPCR. To support the role of miR-630 in breast cancer, we examined the clinical relevance of this miRNA in breast cancer tumours versus matched peritumours. Transfection of miR-630 mimics and inhibitors was used to manipulate the expression of miR-630 to assess effects on response to HER-targeting drugs (lapatinib, neratinib and afatinib). Other phenotypic changes associated with cellular aggressiveness were evaluated by motility, invasion and anoikis assays. TargetScan prediction software, qPCR, immunoblotting and ELISAs, were used to assess miR-630s regulation of mRNA, proteins and their phosphorylated forms.
Drug Response:
sensitive
Cancer basic information
Cancer:
breast cancer
Tissue/Cell:
cell line (SKBR3, HCC1954, SKBR3-Ag, HCC1954-Ag)
Other information
Title:
miR-630 targets IGF1R to regulate response to HER-targeting drugs and overall cancer cell progression in HER2 over-expressing breast cancer.
Journal:
Mol Cancer
Published:
2014
PubMed ID:
24655723